d-sotalol terminates reentry by two mechanisms with different dependence on the duration of the excitable gap

Journal of Pharmacology and Experimental Therapeutics

Volumn 277, Issue 1, 1996, Pages 174-185

  Fei, Hailing ^a   Frame, Lawrence H ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; SOTALOL;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFICACY; DRUG MECHANISM; HEART MUSCLE POTENTIAL; HEART MUSCLE REFRACTORY PERIOD; HEART VENTRICLE TACHYCARDIA; NONHUMAN; PRIORITY JOURNAL; REENTRY ARRHYTHMIA; SUPRAVENTRICULAR TACHYCARDIA;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; DOGS; HEART CONDUCTION SYSTEM; REFRACTORY PERIOD, ELECTROPHYSIOLOGICAL; SOTALOL; TIME FACTORS;

EID: 0030439767     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. BARBEY, J. T., ECHT, D. S., THOMPSON, K. A., RODEN, D. M. AND WOOSLEY, R. L.: Effect of d-sotalol on ventricular arrhythmias in man. Circulation 72: III-170, 1985.
2. BERNSTEIN, R. C. AND FRAME, L. H.: Ventricular reentry around a fixed barrier. Resetting with advancement in an in vitro model. Circulation 81: 267-280, 1990.
3. BORGGREFE, M., HIEF, C., CHEN, X., HAVERKAMP, W. AND HINDRICKS, G.: Acute and long-term efficacy of oral sotalol in patients with sustained ventricular tachycardia or out of hospital cardiac arrest. Circulation 86: 1-533, 1992.
4. BOYDEN, P. A. AND GRAZIANO, J. N.: Activation mapping of reentry around an anatomical barrier in the canine atrium: Observations during the action of the class III agent, d-Sotalol. J. Cardiovasc. Electrophysiol. 4: 266-279, 1993.
5. BRACHMANN, J., SCHOELS, W., WALDECKER, B., SENGES, J., SCHMITT, C. AND KUEBLER, W.: Antiarrhythmic effects of the Class III drug d-sotalol on recurrent sustained ventricular tachycardia - long-term efficacy. J. Am. Coll. Cardiol. 9 (2): 229A, 1987.
6. BRUGADA, J., BOERSMA, L., NAVARRO-LOPEZ, F. AND ALLESSIE, M.: Class III actions in an experimental model of ventricular tachycardia. Eur. Heart J. 14: (suppl. H), 50-55, 1993.
7. CAMPBELL, T. J.: Cellular electrophysiological effects of d- and dl-sotalol in guinea-pig sinoatrial node, atrium and ventricle and human atrium: Differential tissue sensitivity. Br. J. Pharmacol. 90: 593-599, 1987.
8. CARMELIET, E.: Electrophysiologic and voltage clamp analysis of the effects of sotalol on isolated cardiac muscle and Purkinje fibers. J. Pharmacol. Exp. Ther. 232: 817-825, 1985.
9. COLATSKY, T. J., FOLLMER, C. H. AND STARMER, C. F.: Channel specificity in antiarrhythmic drug action: Mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias. Circulation 82: 2235-2242, 1990.
10. CULLING, W., PENNY, W. J. AND SHERIDAN, D. J.: Effects of sotalol on arrhythmias and electrophysiology during myocardial ischemia and reperfusion. Cardiovasc. Res. 18: 397-404, 1984.
11. FELD, G. AND SHAHANDEH-RAD, F.: Activation patterns during termination of canine atrial flutter by the antiarrhythmic drug d-sotalol. PACE 14: 742, 1991.
12. FELD, G. K.: Pharmacologic conversion and suppression of experimental canine atrial flutter: Differing effects of d-sotalol, quinidine, and lidocaine and significance of changes in refractoriness and conduction. Circulation 74: 197-204, 1986.
13. FRAME, L. H.: Antiarrhythmic agents: Is the current classification useful? In Tachycardias: Mechanisms and Management, ed. by M. E. Josephson and H. J. J. Wellens, pp. 335-347, Futura Publishing Company, Inc., Mount Kisco, NY, 1993.
14. FRAME, L. H. AND FEI, H.: D-Sotalol terminates reentry by two mechanisms with different dependence on the duration of the excitable gap (abstract). Circulation 82: II-507, 1991.
15. FRAME, L. H., PAGE, R. L., BOYDEN, P. A., FENOGLIO, J. J., JR. AND HOFFMAN, B. F.: Circus movement in the canine atrium around the tricuspid ring during experimental atrial flutter and during reentry in vitro. Circulation 76: 1155-1175, 1987.
16. FRAME, L. H., PAGE, R. L. AND HOFFMAN, B. F.: Atrial reentry around an anatomic barrier with a partially refractory excitable gap: A canine model of atrial flutter. Circ. Res. 58: 495-511, 1986.
17. FRAME, L. H. AND RHEE, E. K.: Spontaneous termination of reentry after one cycle or short non-sustained runs: Role of oscillations and excess dispersion of refractoriness. Circ. Res. 68: 493-502, 1991.
18. FRAME, L. H., RHEE, E. K., FEI, H. AND LUCHBTTI, W.: Proarrhythmic and antiarrhythmic effects of flecainide on nonsustained reentry around the canine atrial tricuspid ring in vitro. PACE 14: 1728-1734, 1991.
19. FRAME, L. H. AND SIMSON, M. B.: Oscillations of conduction, action potential duration and refractoriness: A mechanism for spontaneous termination of reentrant tachycardias. Circulation 78: 1277-1287, 1988.
20. HAYWARD, R. P. AND TAGGART, P.: Effect of sotalol on human atrial action potential duration and refractoriness: Cycle length dependency of class III activity. Cardiovasc. Res. 20: 100-107, 1986.
21. HONDEGHEM, L. M. AND SNYDERS, D. J.: Class III antiarrhythmic agents have a lot of potential but a long way to go: Reduced effectiveness and dangers of reverse use dependence. Circulation 81: 686-690, 1990.
22. INOUE, H., YAMASHITA, T., UAUI, M., NOZAKI, A. AND SUGIMOTO, T., Antiarrhythmic drugs preferentially produce conduction block at the area of slow conduction in reentrant circuit of canine atrial flutter: Comparative study of disopyramide, flecainide, and E-4031. Cardiovasc. Res. 25: 223-229, 1991.
23. ITO, H. AND GLASS, L.: Theory of reentrant excitation in a ring of cardiac tissue. Physica D 56: 84-106, 1992.
24. JORDAENS, L., GORGELS, A., STROOBANDT, R. AND TEMMERMAN, J.: Efficacy and safety of intravenous sotalol for termination of paroxysmal supraventricular tachycardia. Am. J. Cardiol. 68: 35-40, 1991.
25. KUCHAR, D., GARAN, H., VENDITTI, J., FINKELSTEIN, D., ROTTMAN, J., MCCOMB, J., MCGOVERN, B. AND RUSKIN, J.: Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts. Am. J. Cardiol. 64: 33-36, 1989.
26. LYNCH, J. J., COSKEY, L. A., MONTGOMERY, D. G. AND LUCCHESI, B. R.: Antiarrhythmic and antifibrillatory actions of the levo- and dextrorotatory isomers of sotalol. J. Cardiovasc. Pharmacol. 6: 1132-1141, 1984.
27. MASON, J. W., FOR THE ELECTROPHYSIOLOGIC STUDY VERSUS ELECTROCARDIOGRAPHIC MONITORING INVESTIGATORS: A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. N. Engl. J. Med. 329: 445-451, 1993.
28. NADEMANEE, K., FELD, G. K., HENDRICKSON, J. A., SINGH, P. N. AND SINGH, B. N.: Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular arrhythmias. Circulation 72: 555-564, 1985.
29. ORTIZ, J., IGARASHI, M., GONZALES, X., WALDO, A. L. AND JOHNSON, N. J.: Mechanism of atrial flutter termination by WAY-123,398, a unique class III agent. Circulation 84: II-507, 1991.
30. PATTERSON, E. AND LUCCHESI, B. R.: Antifibrillatory properties of the beta-adrenergic receptor antagonists, nadolol, sotalol, atenolol and propranolol, in the anesthetized dog. Pharmacology 28: 121-129, 1984.
31. PINTO, J. M. B., GRAZIANO, J. N. AND BOYDEN, P. A.: Endocardial mapping of reentry around an anatomical barrier in the canine right atrium: Observations during the action of the Class IC agent, flecainide. J. Cardiovasc. Electrophysiology 4: 672-685, 1993.
32. RACKER, D. K., URSELL, P. C. AND HOFFMAN, B. F.: Anatomy of the tricuspid annulus. Circumferential myofibers as the structural basis for atrial flutter in a canine model. Circulation 84: 841-851, 1991.
33. RENSMA, P. L., ALLESSIE, M. A., LAMMERS, W. J. E. P., BONKE, F. I. M. AND SCHALIJ, M. J.: Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ. Res. 62: 395, 1988.
34. SAHAR, D. I., REIFFEL, J. A., BIGGER, J. T. AND SQUATRITO, A.: Efficacy, safety, and tolerance of d-sotalol in patients with refractory supraventricular arrhythmias. Am. Heart J. 117 (3): 562-568, 1989
35. SIMSON, M. B., SHINNAR, M. AND FRAME, L. H.: Why do some reentrant tachycardias stop (Abstract)? Circulation 78: II-156, 1988.
36. SINGH, B. N. AND VAUGHAN WILLIAMS, E. M.: A third class of anti-arrhythmic action: Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474. Br. J. Pharmacol. 39: 675-687, 1970.
37. SOMANI, P. AND BACHAND, R T.: Blockade of cardiac effects of isoproterenol by the stereoisomers of sotalol. Eur. J. Pharmacol. 7: 239-247, 1969.
38. SPINELLI, W. AND HOFFMAN, B. F.: Mechanisms of termination of reentrant atrial arrhythmias by Class I and Class II antiarrhythmic agents. Circ. Res. 65: 1565-1579, 1989.
39. STRAUSS, H. C., BIGGER, J. T., JR. AND HOFFMAN, B. F.: Electrophysiological and beta-receptor blocking effects of MJ1999 on dog and rabbit cardiac tissue. Circ. Res. 26: 661-678, 1970.
40. TAGGART, P., SUTTON, P. AND DONALDSON, R.: d-Sotalol: A new potent class III anti-arrhythmic agent. Clin. Sci. 69: 631-636, 1985.
41. TASK FORCE OF THE WORKING GROUP ON ARRHYTHMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY: The Sicilian Gambit: A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 84: 1831-1851, 1991.
42. WANG, J., FENG, J. AND NATTEL, S.: Class III antiarrhythmic drug action in experimental atrial fibrillation. Circulation 90: 2032-2040, 1994.
43. WU, K. M. AND HOFFMAN, B. F.: Effect of procainamide and N-acetylprocain-amide on atrial flutter: Studies in vivo and in vitro. Circulation 76: 1397-1408, 1987.